about
Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy.Pazopanib: an antiangiogenic drug in perspective.The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer.Implication of miRNA in the diagnosis and treatment of breast cancer.The present and future of gene profiling in breast cancer.Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications.Mutational analysis of BRCA1 and BRCA2 genes in Peruvian families with hereditary breast and ovarian cancer.Prolonged disease control in a patient with anthracycline- and taxane-resistant breast cancer.Targeted therapies: Combined lapatinib and paclitaxel in HER2-positive breast cancer.The implementation of the Plan Esperanza and response to the imPACT Review.Glioblastoma of pineal region: report of four cases and literature review.Prognostic factors for patients with newly diagnosed brain metastasis from breast cancer.Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America.Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group.PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.Association between mammographic features and response to neoadjuvant chemotherapy in locally advanced breast carcinoma.MGMT promoter methylation in Peruvian patients with glioblastoma.Clinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy.Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group oCritical review of axillary recurrence in early breast cancerDistribution of tumor-infiltrating immune cells in glioblastomaPhase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumorsBreast cancer subtype and survival among Indigenous American women in PeruPrognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple negative breast cancer patients after neo-adjuvant chemotherapyBehaviour of breast cancer molecular subtypes through tumour progressionImpact of pathological features of brain metastases in prognosis[Tuberculosis That Mimics Cancer: Cases Referred to the National Institute of Neoplastic Diseases, Lima-Peru]Level of tumor-infiltrating lymphocytes and density of infiltrating immune cells in different malignanciesHelicobacter Pylori Detected in Tap Water of Peruvian Patients with Gastric CancerRelationship between tumor-associated immune infiltrate and p16 staining over clinicopathological features in acral lentiginous melanomaRole of undifferentiation markers and androgen receptor expression in triple-negative breast cancer
P50
Q37323748-83B8C10F-C171-4BF7-B35E-69B5326D452DQ37630567-E5D9729B-AF0A-42E8-8CB5-BAB9700B9CD3Q37797943-D0C78BC3-B4A8-4B49-8A63-35DD0892F495Q37931898-B36DB5B9-E7B3-4934-9946-7F783A9908D4Q37962377-6B841050-4E3B-4B41-9579-1BCE5243267CQ41059996-8CE82DD1-CE25-429E-B39F-EBD8DCA10B13Q41696477-419F1800-1817-4E19-AE1E-134166F68B64Q43236876-31A3A345-0A52-4BF9-8FB8-E3E082881F7AQ45988803-0422A72F-8D01-470E-9797-919E0D8F8CEAQ47293214-67359C48-1083-49EC-9BB4-BF680163CE14Q48027884-AFD32701-78DC-421F-A8F4-386CD499ABF6Q48213913-C44CA0A1-635D-4C81-ACBF-8FE6B50FF227Q48333472-B6BD7BBC-BB46-427F-9FAA-00FD660CCA97Q48850918-A9266FE9-EA03-4EDB-8553-E62D7A02DE22Q54304875-B24D33D7-9286-446B-A973-55F8BA44B3D9Q55070764-9133EA37-F943-4F80-9B21-83F1FB7BC5D1Q55140281-F7CB3372-1A82-4CD2-8334-9CE1B7D64981Q55275119-7DF28365-B4FD-4F01-8E93-E0CA9233D836Q57105469-68310C06-F25F-41C5-A210-93F1AACFF2D8Q57106758-425EA50B-0B63-44A5-99E4-52EBE9481450Q57288270-BEDF8883-C413-4155-B851-813D1E6DE377Q58289073-59DC32BC-BAFB-4FB2-A329-31FBB6C5ECE0Q58763770-1CD2A716-3A0E-4823-90A1-822423C5E66AQ60681783-CF1B6BA3-2BC2-4629-8F57-011F9AA6B19DQ84225868-9638A7A1-9E4F-44F3-9634-F247C0CEFE31Q88480224-347C064E-5D7D-4FBB-B10C-88787BB6E0A5Q89165669-723E9CE9-930B-4BA5-AE99-DB92517601AFQ90765065-83367974-A1D4-467A-888E-2DDD548603A3Q91411543-404E5FD1-9FF8-4A91-AEDA-F1EA33014E81Q91696224-F4C5E825-4113-4908-9767-DE2B979ECEDEQ92099466-2FC1FBC2-6178-4F9F-A89A-D89FC79359EF
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Carlos A Castaneda
@ast
Carlos A Castaneda
@en
Carlos A Castaneda
@es
Carlos A Castaneda
@nl
type
label
Carlos A Castaneda
@ast
Carlos A Castaneda
@en
Carlos A Castaneda
@es
Carlos A Castaneda
@nl
prefLabel
Carlos A Castaneda
@ast
Carlos A Castaneda
@en
Carlos A Castaneda
@es
Carlos A Castaneda
@nl
P106
P1153
35263574400
P31
P496
0000-0001-6200-0856